wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1046.
1 2 3 4 5 ... 21 Next »

Medicine/Pharmacology - Life Sciences
23.02.2017
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
Priority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs.
Medicine/Pharmacology - Mechanical Engineering/Mechanics
21.02.2017
Innovation cannot be taught; it must be learned
Innovation cannot be taught; it must be learned
ETH President Lino Guzzella welcomed Alexander van der Bellen to the University on Friday, where the Austrian President was shown how ETH is encouraging innovation.
Environment/Sustainable Development - Medicine/Pharmacology
21.02.2017
Selenium deficiency promoted by climate change
Selenium deficiency promoted by climate change
As a result of climate change, concentrations of the trace element selenium in soils are likely to decrease.
Medicine/Pharmacology - Life Sciences
18.02.2017
Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Phase II study supports potential for Roche's TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma Proof of concept study in first line mRCC (a type of kidney cancer) shows that TECENTRIQ and Avastin can be combined with a manageable safety profile Study results also showed encouraging efficacy compared to sunitinib in those people whose disease expressed the PD-L1 (programmed de
Computer Science/Telecom - Medicine/Pharmacology
06.02.2017
Switzerland Launches a National Center for Data Science
Switzerland Launches a National Center for Data Science
Switzerland is creating a National Center for Data Science to foster innovation in data science, multidisciplinary research and open science.
Medicine/Pharmacology - Life Sciences
31.01.2017
Novartis drug Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC
Votubia is the first adjunctive treatment approved in the EU specifically for partial-onset seizures in children and adults with tuberous sclerosis complex (TSC)   Approval addresses unmet need as up
Medicine/Pharmacology - Life Sciences
27.01.2017
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Spin-off Cellestia Biotech raises CHF 8 million in seed financing
Cellestia Biotech, an EPFL spin-off, can now carry out clinical trials on its new cancer treatment after raising CHF 8 million in seed money.
Life Sciences - Medicine/Pharmacology
26.01.2017
LSD alters perception via serotonin receptors
Humans perceive everyday things and experiences differently and attach different meaning to pieces of music, for instance. In the case of psychiatric disorders, this perception is often altered. For patients suffering from addictions, for instance, drug stimuli are more meaningful than for people without an addiction.
Medicine/Pharmacology
26.01.2017
Alcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
Innovative AcrySof IQ PanOptix Toric i ntraocular lens (IOL) extends Alcon's trifocal PanOptix IOL portfolio to a wider range of patients   CE-marked in November 2016, this IOL offers excellent near
Medicine/Pharmacology - Environment/Sustainable Development
26.01.2017
Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
Novartis Access-to-medicine programs reached approximately 52 million patients, including first-year deliveries through the innovative Novartis Access program   Novartis improved position in key sust
Medicine/Pharmacology - Business/Economics
26.01.2017
Inability to Work: Medical Experts Often Disagree
Independent medical evaluations are often used to adjudicate disability claims. But different doctors assessing the same patient often disagree on whether the patient is disabled or not. This problem can be mitigated by applying standardized procedures, says an international study led by researchers at the University of Basel and the University Hospital Basel in Switzerland.
Business/Economics - Medicine/Pharmacology
25.01.2017
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback FY net sales (0% cc ) in line with prior year due to st
Life Sciences - Medicine/Pharmacology
23.01.2017
Immune Defense Without Collateral Damage
Immune Defense Without Collateral Damage
Researchers from the University of Basel in Switzerland have clarified the role of the enzyme MPO. In fighting infections, this enzyme, which gives pus its greenish color, produces a highly aggressive acid that can kill pathogens without damaging the surrounding tissue. In the human body's fight against bacterial pathogens, white blood cells are in the front line.
Life Sciences - Medicine/Pharmacology
20.01.2017
Cell fate regulation by LIN41: activity determined by binding location
Helge Großhans and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have elucidated the mode of action of the RNA-binding protein and stem cell factor LIN41. In an animal model, they showed that LIN41 silences four specific mRNAs, by two distinct mechanisms. They found that the choice of mechanism is determined by where on the mRNA LIN41 binds.
Medicine/Pharmacology - Life Sciences
17.01.2017
On track to heal leukaemia
On track to heal leukaemia
Media releases, information for representatives of the media Media Relations (E) The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern's University Hospital and the Department of Clinical Research (DCR) of the University of Bern. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Medicine/Pharmacology - Life Sciences
16.01.2017
Every Meal Triggers Inflammation
When we eat, we do not just take in nutrients - we also consume a significant quantity of bacteria. The body is faced with the challenge of simultaneously distributing the ingested glucose and fighting these bacteria.
Medicine/Pharmacology - Life Sciences
09.01.2017
New insights into mechanisms of breast cancer development and resistance to therapy
Why does breast cancer develop and how come certain patients are resistant to established therapies' Researchers from the University of Basel have gained new insights into the molecular processes in breast tissue. They identified the tumor suppressor LATS as a key player in the development and treatment of breast cancer.
Life Sciences - Medicine/Pharmacology
06.01.2017
Medicine/Pharmacology - Life Sciences
06.01.2017
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated
Life Sciences - Medicine/Pharmacology
06.01.2017
Autoimmunity and Infections: When the Body Fights Itself
Basel-based doctors are on the trail of a possible connection between autoimmune diseases and infections: errors can occur when immune cells absorb certain proteins from pathogen cells. These It is already known that there is a connection between infections and autoimmunity – the inability of an organism to recognize parts of its own body as “self”.
Medicine/Pharmacology - Physics/Materials Science
03.01.2017
Looking back at 2016 (2/2)
Looking back at 2016 (2/2)
Slowing the aging process, improving data security, enabling paraplegics to walk again, transporting vaccines at room temperature to warm countries, creating jobs with the CHF 400 million raised by spin-offs - those are just some of the many areas where EPFL scientists have made a lasting contribution.
Life Sciences - Medicine/Pharmacology
27.12.2016
Looking back at 2016 (1/2)
Looking back at 2016 (1/2)
Health, energy, maths and chocolate: no field of research has been neglected last year by EPFL's scientists.  Cheaper solar cells with 20.2% efficiency Some of the most promising solar cells today use light-harvesting films made from perovskites. However, perovskite-based solar cells use expensive ‘hole-transporting' materials, whose function is to move the positive charges that are generated when light hits the perovskite film.
Medicine/Pharmacology - Life Sciences
23.12.2016
Treating cancer with drugs for diabetes and hypertension
Treating cancer with drugs for diabetes and hypertension
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs. The results of the study have now been published in ‘Science Advances'.
Medicine/Pharmacology - Environment/Sustainable Development
23.12.2016
Fighting cholera by predicting how its spreads
Fighting cholera by predicting how its spreads
In October, EPFL and Médecins Sans Frontières joined forces in an unprecedented effort to predict how the cholera epidemic in Haiti will spread.
Psychology - Medicine/Pharmacology
22.12.2016
Helping pays off: People who care for others live longer
Older people who help and support others live longer. These are the findings of a study published in the journal ‘Evolution and Human Behavior', conducted by researchers from the University of Basel, Edith Cowan University, the University of Western Australia, the Humboldt University of Berlin, and the Max Planck Institute for Human Development in Berlin.
Medicine/Pharmacology
22.12.2016
Roche’s emicizumab for haemophilia A meets primary endpoint in phase III study
Roche's emicizumab for haemophilia A meets primary endpoint in phase III study Emicizumab prophylaxis reduced the number of bleeds over time compared to no prophylaxis in people with haemophilia A an
Medicine/Pharmacology - Life Sciences
21.12.2016
Positive Phase III results for Roche’s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Positive Phase III results for Roche's investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies OCREVUS demonstrated a favourable safety profile in three large Phase III studies Roche announced today that data from three Phase III st
Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Medicine/Pharmacology - Life Sciences
19.12.2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases Novartis to broaden liver portfolio to deliver best-in
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis drug Votubia recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC
If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC)   Seizures are the most common TSC-relat
Medicine/Pharmacology - Life Sciences
16.12.2016
Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes
Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications   Ilaris (canakinumab) is recommended for
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Medicine/Pharmacology - Life Sciences
15.12.2016
Magnetic forces purify the blood
Magnetic forces purify the blood
Every five seconds, someone in the world dies from blood poisoning. Hemotune, a young start-up founded by ETH researchers, is developing a revolutionary blood purification system to address this problem. Lukas Langenegger picks up a small glass ampoule containing a dark, reddish-brown fluid. Then he holds a magnet against the vial, and iron particles accumulate on the edge of the glass as if by magic, leaving behind a crystal-clear fluid.
Medicine/Pharmacology
12.12.2016
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care Lucentis monotherapy , Recent Lucentis EU approval in new choroidal neovascularization (CNV)  indication
Medicine/Pharmacology - Administration/Government
12.12.2016
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health   Program uses smartphones and tablet
Medicine/Pharmacology
12.12.2016
EPFL spinoff QGel raises 12 million dollars from private investors
EPFL spinoff QGel raises 12 million dollars from private investors
QGel is a startup that makes a synthetic gel for growing cells as if they were in the human body. This breakthrough enhances the reliability of research into anti-cancer drugs.
Medicine/Pharmacology
09.12.2016
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone   LEE011 plus letrozole reduced risk of progression or death by 55% over letrozole alone in de
Medicine/Pharmacology - Event
08.12.2016
The R. Geigy Foundation honours efforts to overcome ’neglected tropical diseases
Giovanna Raso and Jean Coulibaly are the awardees of the R. Geigy-Award 2016 and will share a CHF 20,000 prize in honour of their efforts to fight neglected helminth infections in West Africa.
Medicine/Pharmacology
08.12.2016
Back to life
«A few months after the proton treatment was over, I realised that I could see more and more. Just dimly, it's true, but I could see! That was sensational!» More than a year ago, Gabi Meier* was treated with proton therapy at the Paul Scherrer Institute PSI.
Medicine/Pharmacology
08.12.2016
Novartis’ Ultibro Breezhaler improved lung function and COPD symptoms after direct switch from previous treatment
Ultibro Breezhaler improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies   Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients   Data from the pragmatic CRYSTAL study showcased for the first time at the 2016 British Thoracic Society Winter Meeting in Lond
Medicine/Pharmacology - Life Sciences
07.12.2016
Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now approved for nine distinct uses across six different type
Medicine/Pharmacology - Life Sciences
07.12.2016
Novartis’ Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions
Novartis' Lucentis received EU approval in new indication - Lucentis the only treatment available for a wide range of CNV conditions The European Commission approved Lucentis to treat patients for vi
Medicine/Pharmacology
07.12.2016
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
Before an operation, surgeons have to obtain the most precise image possible of the anatomical structures of the part of the body undergoing surgery.
Environment/Sustainable Development - Medicine/Pharmacology
06.12.2016
Phase two of EPFL's expansion in Valais
Phase two of EPFL's expansion in Valais
Patrick Aebischer and Valais State Councilor Esther Waeber-Kalbermatten signing the agreement, in presence of Martin Vetterli and Jean-Michel Cina.
Medicine/Pharmacology - Life Sciences
06.12.2016
Novartis announces Zykadia first-line study results showing 16.6 month progression-free survival in patients with ALK+ advanced NSCLC
Patients without brain metastases at diagnosis experienced median progression-free survival of 26.3 months, the longest seen in a global Phase III study in ALK+ NSCLC   Patients with measurable brain metastases in the Zykadia arm experienced an intracranial response rate of more than 70%   Data will be used to support global regulatory submissions for first-line use of Zykadia in ALK+ advanced NSCLC patients - Novartis today announced result
Medicine/Pharmacology - Life Sciences
05.12.2016
New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product
ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product Interim data in over 600 adults show potential of GP2013 as an alternative rituximab Sandoz proposed biosimilar rituximab is the company's first monoclonal antibody candidate Holzkirchen, December 5, 2016 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial.
Medicine/Pharmacology
05.12.2016
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
Findings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)     Patients reported a diminished capacity of more than 35% when trying to work, highlighting reduction in quality of life can extend to the workplace   First international survey of 699 patients with an MPN, specifically myelofibrosis, polycythemia vera or essential thrombocythem
Medicine/Pharmacology - Chemistry
05.12.2016
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna from Glivec
ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients The Tasigna TFR trials, including ENESTop, demonstrate our continued commitment to the CML community - Novartis today announced at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition new data from the Tasigna (nilotinib) ENESTop Treatment-free Remission (TFR) study, which demonstrate that TFR rates are c
Medicine/Pharmacology - Life Sciences
05.12.2016
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Re-emergence of Syphilis Traced to Pandemic Strain Cluster
Syphilis has plagued humankind for over 500 years. After the first reported outbreaks struck Europe in 1495, the disease spread rapidly to other continents and swelled to a global pandemic. When treatment with the antibiotic penicillin became available in the mid-twentieth century, infection rates started to decrease dramatically.
1 2 3 4 5 ... 21 Next »